Clinical observation on the treatment of joint swelling and pain due to the Fengtabuzu syndrome of RA by Dai medicine Longmengshahousan

Yunnan Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Meet the 2010 ACR/EULAR DIAGNOSTIC criteria for RA;
•(2) It conforms to the diagnostic criteria of Fengtabuzu syndrome;
•(3) Between the ages of 18 and 70, regardless of gender;
•(4) the hands joint X-ray stage I and II, joint function class I and II, III;
•(5) 2.6 < DAS28 < 5.1;
•(6) Pain or swelling of at least two wrists;
•(7) Patients who use hormones, hormone-suspected substances or biological agents need to stop taking drugs for more than 3 months;
•(8) No non-steroidal anti-inflammatory drugs or topical analgesics were used at least 1 week before enrollment.
•(9) Voluntary subjects signed informed consent.

•(1) Patients with other rheumatic immune diseases, such as systemic lupus erythematosus, Sjogren's syndrome, and severe osteoarthritis;
•(2) Complicated with cardiovascular, pulmonary, liver, gastrointestinal, kidney, hematopoietic system or tumor, or complicated with various acute or chronic infections or other infectious diseases (hepatitis, tuberculosis, etc.);
•(3) Local skin damage, infection or trauma of the tested joint is not healed;
•(4) Those who did not respond to the treatment of methotrexate or leflunomide;
•(5) A history of contraindications to experimental drugs (pulmonary interstitial fibrosis, etc.) and allergies;
•(6) A history of alcoholism, drug addiction or neuropsychiatric disorders (epilepsy, depression, etc.);
•(7) Pregnant or lactating women who have recently had family planning;
•(8) Participating in other drug clinical studies.

发起方